Serotonergic drugs and valvular heart disease
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The serotonin (5-HT) releasers (+/-)-fenfluramine and (+)-fenfluramine were withdrawn from clinical use owing to increased risk of valvular heart disease. One prevailing hypothesis (i.e., the '5-HT hypothesis') suggests that fenfluramine-induced increases in plasma 5-HT underlie the disease. OBJECTIVE: Here, we critically evaluate the possible mechanisms responsible for fenfluramine-associated valve disease. METHODS: Findings from in vitro and in vivo experiments performed in our laboratory are reviewed. The data are integrated with existing literature to address the validity of the 5-HT hypothesis and suggest alternative explanations. CONCLUSIONS: The overwhelming majority of evidence refutes the 5-HT hypothesis. A more likely cause of fenfluramine-induced valvulopathy is activation of 5-HT(2B) receptors on heart valves by the metabolite norfenfluramine. Future serotonergic medications should be designed to lack 5-HT(2B) agonist activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895 · cited 1×
“With the exception of the 5-HT3 receptor subtype, which is a transmitter-gated ion channel, 5-HT receptors are members of the 7-transmembrane G-protein-coupled receptor superfamily [3].”
BackgroundRothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722 · cited 5×
“Therefore, in a separate set of experiments, we investigated whether stereoisomers of fenfluramine or norfenfluramine might directly activate specific 5-HT receptor subtypes mediating mitogenic effects [39].”
BackgroundInfluentialSelf-citationDrugs and Valvular Heart Disease
Roth, B. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068265 · Cited by 479 · cited 9×
“These predictions have been borne out by subsequent clinical investigations [18,79].”
BackgroundResultInfluentialZannad, F., Gille, B., Grentzinger, A., Bruntz, J.-F., Hammadi, M., Boivin, J.-M., Hanotin, C., Igau, B., & Drouin, P. (2002) · American Heart Journal · doi:10.1067/mhj.2002.124403 · Cited by 71 · cited 1×
“Echocardiographic studies in humans support the assertion that fluoxetine (and other SSRIs) [65], phentermine [66] and sibutramine (a NE/5-HT uptake inhibitor) [67] do not cause VHD.”
Background
Cited by
A non-hallucinogenic psychedelic analogue with therapeutic potential
Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., McCarroll, M. N., Taylor, J. C., Myers-Turnbull, D., et al. (2021) · Nature · doi:10.1038/s41586-020-3008-z · Cited by 473
The FDA's Assessment of Two Drugs for Chronic Weight Management
Colman, E., Golden, J., Roberts, M., Egan, A., Weaver, J., & Rosebraugh, C. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1211277 · Cited by 342
Serotonin controlling feeding and satiety
Voigt, J.-P., & Fink, H. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.08.065 · Cited by 312
Centrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151
Update on obesity pharmacotherapy
Bray, G. A., & Ryan, D. H. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12328 · Cited by 88
Metadata
- Authors
- Rothman, R. B., & Baumann, M. H.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2009-05
- Volume
- 8
- Issue
- 3
- Pages
- 317-329
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2093372242
- Cited by
- 139
- References
- 5
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serotonergic drugs and valvular heart disease. https://app.cochat.ai/papers/10.1517/14740330902931524
- The paper
- Rothman, R. B., & Baumann, M. H. (2009). Serotonergic drugs and valvular heart disease. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740330902931524
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.